HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Skinvisible marketing deal

This article was originally published in The Rose Sheet

Executive Summary

Firm cancels previously announced agreement with Health First Distributors North America, which included exclusive marketing and distribution rights for Skinvisible 1% triclosan antimicrobial hand sanitizer lotion. Canada-based Health First did not submit a second nonrefundable deposit of $100,000 by Nov. 30, as required by a letter of intent signed Oct. 29, according to Skinvisible. Health First began shipping the product to Walgreens Nov. 12 (1"The Rose Sheet" Nov. 24, 2003, Marketing In Brief)...

You may also be interested in...



Marketing In Brief

Rembrandt: Nighttime Whitening features peroxide gel tooth whitening formula in simple sponge tip applicator system, Den-Mat announces. Sponge applicator turns with click to self-dispense gel on teeth. Gel then forms a "paste-like masque" and dissolves overnight to provide brighter, whiter teeth, according to Den-Mat. Nighttime Whitening is recommended for use alone or in combination with one of Rembrandt's tooth-bleaching kits. The product is available now for $14.95...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel